3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gynecologic
1
Conditions
Breast Neoplasms
22
Neoplasm Metastasis
10
Stomach Neoplasms
5
Colorectal Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Esophageal Neoplasms
3
Brain Neoplasms
3
Adenocarcinoma
3
Triple Negative Breast Neoplasms
2
Recurrence
2
Neoplasms
2
Meningeal Carcinomatosis
2
HER2-positive Breast Cancer
2
Breast Cancer With Brain Metastasis
2
Unresectable Locally Recurrent Breast Cancer
1
Salivary Gland Neoplasms
1
Rectal Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neoplasm, Residual
1
Inflammatory Breast Neoplasms
1
HER2-negative Breast Cancer
1
HER2-mutant Non-Small Cell Lung Cancer
1
HER2-low Hormone Receptor Positive Breast Cancer
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Gastric Adenocarcinoma
1
Colonic Neoplasms
1
Carcinoma
1
Interventions
Cyclophosphamide
58
Dexamethasone
50
Rituximab
39
Peripheral Blood Stem Cell Transplantation
29
Paclitaxel
29
Lenalidomide
28
fludarabine phosphate
27
Gemcitabine
26
Etoposide
26
Bortezomib
26
Cytarabine
25
Busulfan
24
pembrolizumab
21
Radiotherapy
21
Bevacizumab
21
Carboplatin
20
Mycophenolic Acid
19
Melphalan
19
Cisplatin
19
Filgrastim
18
pomalidomide
17
fludarabine
17
Oxaliplatin
17
Antilymphocyte Serum
17
Cyclosporine
16
Tacrolimus
15
Methotrexate
15
Whole-Body Irradiation
14
Methylprednisolone
13
Bendamustine Hydrochloride
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Recurrence
×
trastuzumab deruxtecan
×
Clear all
NCT07340164
2026-04-20
TROY
Yonsei University
Phase 2
Recruiting
116 enrolled
NCT05704829
2025-11-19
ADAPTHER2-IV
West German Study Group
Phase 2
Active not recruiting
402 enrolled